Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Urologie
Erschienen in: Der Urologe 4/2006

01.09.2006 | Leitthema

Das Nierenzellkarzinom

verfasst von: PD Dr. A. Haferkamp, D. Rohde, S. C. Müller, H. Rübben, M. Hohenfellner

Erschienen in: Die Urologie | Sonderheft 4/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Seit seiner Entdeckung vor 165 Jahren haben sich sowohl in der Diagnostik als auch in der Therapie des Nierenzellkarzinoms große Fortschritte bemerkbar gemacht. Während zunächst eine Standardisierung der Operationstechnik zu einer deutlich verbesserten Langzeitprognose der Patienten führte, sorgte die Einführung von Sonographie, Computertomographie (CT) und Magnetresonanztomographie (MRT) dafür, dass vermehrt kleine inzidentelle Karzinome detektiert wurden, was wiederum in einer besseren Prognose resultierte. Neuere Operationstechniken wie die organerhaltende Tumorresektion oder minimal-invasive Verfahren führten zu weiteren Verbesserungen der operativen Therapie. Beim metastasierten Nierenzellkarzinom stellt die Immuntherapie mit Zytokinen eine wichtige Säule zur Behandlung der Patienten dar. Neue Substanzen, die Faktoren für Tumorzellwachstum und Angiogenese inhibieren, eröffnen neue Therapieansätze, die sich in den nächsten Jahren verstärkt durchsetzen werden.
Literatur
1.
Alamdari FI, Ljungberg B (2005) Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system. Scand J Urol Nephrol 39: 277–282CrossRefPubMed
2.
Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 227: 177–186
3.
Amin MB, Corless CL, Renshaw AA et al. (1997) Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 21: 621–635CrossRefPubMed
4.
Amin MB, Tamboli P, Javidan J et al. (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26: 281–291CrossRefPubMed
5.
Argani P, Antonescu CR, Illei PB et al. (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma. A distinctive tumor entity previously included among renal cell carcinoma of children and adolescents. Am J Pathol 159: 179–192PubMed
6.
Argani P, Antonescu CR, Couturier J et al. (2002) PRCC-TFE3 renal carcinomas. Morphologic, immunhistochemical, ultrastructural and molecular analysis of an entity associated with the t(X;1) (p11.2;q21). Am J Surg Pathol 26: 1553–1566CrossRefPubMed
7.
Atkins MB, Hidalgo M, Stadler WM et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–918CrossRefPubMed
8.
Atzpodien J, Buer J, Sel S et al. (1999) Chemoimmuntherapie des fortgeschrittenen Nierenzellkarzinoms. Urologe A 38: 474–478CrossRefPubMed
9.
Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2 and interferon alfa-2a based immunochemotherapy in advanced renal cell carcinoma: a prospective randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group. J Clin Oncol 22: 1174–1176CrossRefPubMed
10.
Atzpodien J, Schmitt E, Gertenbach U et al. (2005) Adjuvant treatment with Interleukin-2 and Interferon-α2a based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomized Trail of the German Cooperative Renal Carcinoma chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843–846CrossRefPubMed
11.
Bakal CW, Cynamon J, Lakritz PS, Sprayregen S (1993) Value of preoperative renal artery ambolization in reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. J Vasc Interv Radiol 4: 727–731PubMed
12.
Baltarovich OH, Kurtz AB (1987) Sonographic evaluation of renal masses. Urol Radiol 9: 79–87PubMed
13.
Beare JB, McDonald JR (1949) Involvement of renal capsule in surgically removed hypernephroma: gross and histopathologic study. J Urol 61: 857
14.
15.
Becker F, Siemer S, Humke U et al. (2006) Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 Patients. Eur Urol 49: 308–313CrossRefPubMed
16.
Belardelli F, Ferrantini M, Parmiani G et al. (2004) International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 64: 6827–6830CrossRefPubMed
17.
Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC et al. (2006) A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175: 57–62CrossRefPubMed
18.
Blom JH, van Poppel H, Marechal JM et al. (1999) Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. Eur Urol 36: 570–575CrossRefPubMed
19.
Bregni M, Dodero A, Peccatori J et al. (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99: 4234–4236CrossRefPubMed
20.
Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin 2. Cancer 80: 1198–1220CrossRefPubMed
21.
Chan DY, Cadeddu JA, Jarrett TW et al. (2001) Laparoscopic radical nephrectomy: cancer control for renal cell carcinoma. J Urol 166: 2095–2100CrossRefPubMed
22.
Cheville JC, Blute Ml, Zincke H et al. (2001) Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 166: 453–456CrossRefPubMed
23.
Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750–758CrossRefPubMed
24.
Chow WH, Gridley G, Fraumeni JF, Järvholm B (2000) Obesity, hypertension and the risk of kidney cancer in man. N Engl J Med 343: 1305–1311CrossRefPubMed
25.
Clark JI, Atkins MB, Urba WJ et al. (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133–3140CrossRefPubMed
26.
27.
Coppin C, Porszolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 25; CD001325
28.
Corica FA, Iczkowski KA, Cheng L et al. (1999) Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long term follow up. J Urol 161: 408–411CrossRefPubMed
29.
Dave DS, Lam JS, Leppert JT, Belldegrun AS (2005) Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. BJU Int 96: 1268–1274CrossRefPubMed
30.
Davis CJ, Mostofi FK, Sesterhenn IA (1995) Renal medullary carcinoma: a seventh sickle cell nephropathy. Am J Surg Pathol 19: 1–11PubMed
31.
Delahunt B, Thornton A (1996) Renal cell carcinoma. A historical perspective. J Urol Pathol 4: 31–39
32.
Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunhistochemical study of 105 tumors. Mod Pathol 10: 537–544PubMed
33.
Delahunt B, Eble J (2005) History of the development of the classification of renal cell neoplasia. Clin Lab Med 25: 231–246CrossRefPubMed
34.
Deutsche Krebsgesellschaft (2002) AWMF Nierenzellkarzinom, AWMF Leitlinienregister Nr.032/037, 3. Aufl. Deutsche Krebsgesellschaft
35.
Dhote R, Pellicer-Coeuret M, Thiounn N et al. (2000) Risk factors for adult renal cell carcinoma: a systemic review and implications for prevention. BJU Int 86: 20–27CrossRefPubMed
36.
Dickinson WH (1885) On renal and urinary affections, vol. 3. Longmans Green, London
37.
Dillenburg W, Poulakis V, Skriapa K et al. (2006) Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: Quality of life, pain and reconvalescence. Eur Urol 49: 314–323CrossRefPubMed
38.
Dos Santos R (1934) L’aortographie dans les tumeurs rénales et pararénales. Arch Mal Reins 8: 313
39.
Dunn MD, Portis AJ, Shalhav AL et al. (2000) Laparoscopic versus open radical nephrectomy: a 9-year experience. J Urol 164: 1153–1159CrossRefPubMed
40.
Eble JN, Bonsib SM (1998) Extensively cystic renal neoplasms: cystic nephroma, cystic partially differentiated nephroblastoma, multilocular cystic renal cell carcinoma, cystic hamartoma of renal pelvis. Sem Diag Pathol 15: 2–20
41.
Eble JN, Sauter G, Epstein JI et al. (2004) Pathology and genetics of tumours of the ruinary system and male genital organs.World Health Organization Classification of Tumours. IARC Press, Lyon
42.
Escudier B, Szcylik C, Eisen T et al. (2005) Randomised phase III trial of the raf kinase and VEGFR inhibitor sorafenib (Bay 43–9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 23: 4510
43.
Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326: 1456–1463PubMed
44.
Fischedick AR, Peters PE, Kleinhans G, Pfeifer E (1987) Preoperative renal tumor embolization. A useful procedure? Acta Radiol 28: 303–306PubMed
45.
Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by Interferon alfa-2b compared with Interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–1659CrossRefPubMed
46.
Flanigan RC, Mickisch G, Sylvester R et al. (2004) Cytoreduktive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071–1076CrossRefPubMed
47.
Fornara P, doehn C, Seyfarth M, Joacham D (2000) Why is urological laparoscopy minimally invasive? Eur Urol 37: 241–250CrossRef
48.
Fyfe G, Fisher RI, Rosenberg SA et al. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696PubMed
49.
George D, Michaelson D, Oh WK et al. (2003) Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22: 385
50.
Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. in Zusammenarbeit mit dem Robert Koch Institut Krebs in Deutschland (2006) Häufigkeiten und Trends, 5. überarbeitete Aufl. RO BO Print, Riegelsberg
51.
Gettman MT, Blute ML, Spotts B et al. (2001) Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91: 354–361CrossRefPubMed
52.
Giberti C, Oneto F, Martorana G et al. (1997) Radical nephrectomy for renal cell carcinoma: long term results and prognostic factors on a series of 328 cases. Eur Urol 31: 40–48PubMed
53.
Gill IS, Matin SF, Desai MM et al. (2003) Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 170: 64–68CrossRefPubMed
54.
Gill IS, Remer EM, Hasan WA et al. (2005) Renal cryoablation: outcome at 3 years. J Urol 173: 1903–1907CrossRefPubMed
55.
Gitlitz BJ, Figlin RA (2003) Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 30: 589–600CrossRefPubMed
56.
Gold PJ, Thompson JA, Markowitz DR et al. (1997) Metastatic renal cell carcinoma: Long-term survival after therapy with high dose continuous infusion interleukin-2. Cancer J Sci Am 3: 85–91
57.
Grawitz P (1883) Die sogenannten Lipome der Niere. Arch Pathol Anat 93: 39CrossRef
58.
Grawitz P (1884) Die Entstehung von Nierentumoren aus Nebennierengewebe. Verh Deutsch Ges Chir 13: 28
59.
Grégoire R (1905) Procédé de néephrectomie pour cancer. Ann Mal Org Géen Urin 23: 179
60.
Guinan P, Sobin LH, Algaba F et al. (1997) TNM staging of renal cell carcinoma. Cancer 80: 992–993CrossRefPubMed
61.
Guyon F (1881) Lecons cliniques sur les maladies des voies urinaires. J.B. Baillère, Paris
62.
Haferkamp A, Bastian PJ, Pritsch M et al. (2006) Prospective long term follow up of renal cell carcinomas with tumor thrombus extension into the vena cava. J Urol (in press)
63.
Hafez KS, Fergany AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162: 1930–1933CrossRefPubMed
64.
Hainsworth JD, Sosman JA, Spigel DR et al. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889–7896CrossRefPubMed
65.
Han KR, Bui MH, Pantuck AJ et al. (2003) TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 169: 899–903CrossRefPubMed
66.
Hentschke P, Barkholt L, Uzunel M et al. (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31: 253–261CrossRefPubMed
67.
Herczel E (1890) Über Nierenextirpation. Beitr Klin Chir 6: 485
68.
Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 146: 1224–1227PubMed
69.
Heuser L, Friedman G, Modder U et al. (1977) CT Diagnose und Differentialdiagnose von Raumforderungen der Niere. Röntgenblätter 30: 479–489
70.
Holtl L, Zelle-Rieser C, Gander H et al. (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Can Res 8: 3369–3376
71.
Hricak H, Williams RD (1984) Magnetic resonance imaging and its application in urology. Urology 23: 442–445PubMed
72.
Israel GM, Bosniak MA (2003) Renal inmaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am 30: 499–514CrossRefPubMed
73.
Itano NB, Blute ML, Spotts B, Zincke H (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–325CrossRefPubMed
74.
Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51: 203–205CrossRefPubMed
75.
Jocham D, Richter A, Hoffmann L et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599CrossRefPubMed
76.
Judd ES, Hand JR (1929) Hypernephroma. J Urol 22: 10
77.
Kalman D, Varenhorst E (1999) The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol 33: 162–170CrossRefPubMed
78.
Kearney GP, Klein LA, Simon ML et al. (1975) B-mode nephrosonography in renal masses. Its use and some limitations. Urology 6: 125–129CrossRefPubMed
79.
Kennedy SM, Merino MJ, Linehan WM et al. (1990) Collecting duct carcinoma of the kidney. Hum Pathol 21: 449–456CrossRefPubMed
80.
Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991–5004CrossRefPubMed
81.
Kinouchi T, Saiki S, Meguro N et al. (1999) Impact of tumor size on the clinical outcomes of patients with Robson Stage 1 renal cell carcinoma. Cancer 85: 689–695CrossRefPubMed
82.
Kovacs G, Akhtar M, Beckwith BJ et al. (1997) The heidelberg classification of renal cell tumors. J Pathol 183: 131–133CrossRefPubMed
83.
Kreiger N, Marrett LD, Dodds L et al. (1993) Risk factors for renal cell carcinoma: results of a population based case control study. Cancer Causes Cintrol 4: 101–110CrossRef
84.
Lee CT, Katz J, Shi W et al. (2000) Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol 163: 730–736CrossRefPubMed
85.
Leibovich BC, Pantuck AJ, Bui MHT et al. (2003) Current staging of renal cell carcinoma. Urol Clin North Am 30: 481–497CrossRefPubMed
86.
Leibovich BC, Blute ML, Cheville JC et al. (2004) Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171: 1066–1070CrossRefPubMed
87.
Lerner SE, Hawkins CA, Blute ML et al. (2002) Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing surgery. J Urol 167: 884–889PubMed
88.
Licht MR, Novick AC (1993) Nephron sparing surgery for renal cell carcinoma. J Urol 149: 1–7PubMed
89.
Lindor NM, Dechet CB, Greene MH et al. (2001) Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Gen Test 5: 101–106CrossRef
90.
Lubarsch O (1894) Beiträge zur Histologie der von Nebennierenkeimen ausgehenden Nierengeschwülste. Arch Pathol Anat 135: 149CrossRef
91.
Marten A, Flieger D, Renoth S et al. (2002) Therapeutic vaccination against metastatic renal cell carcinomaby autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51: 637–644CrossRefPubMed
92.
McCredie M, Ford JM, Stewart JH (1988) Risk factors for cancer of renal parenchyma. Int J Cancer 42: 13–16PubMed
93.
McCredie M, Pommer W, McLaughlin JK et al. (1995) International renal-cell cancer study – analgetics. Int J Cancer 60: 345–349PubMed
94.
McDermott DF, Regan MM, Clark JI et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141CrossRefPubMed
95.
Medeiros LJ, Palmedo G, Krigman HR et al. (1999) Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 23: 772–780CrossRefPubMed
96.
Medical Research Cuncil Renal Cancer Collaborators (1999) Interferon-alpa and survival in metastatic renal carcinoma: early results of randomised controlled trials. Lancet 353: 14–17CrossRefPubMed
97.
Mellemgaard A, Niwa S, Mehl ES et al. (1994) Risk factors for renal cell carcinoma in Denmark: Role of medication and medical history. Int J Epifemiol 23: 923–930
98.
Mickisch G, Carballido J, Hellsten S et al. (2001) Guidelines on renal cell cancer. Eur Urol 40: 252–255CrossRefPubMed
99.
Mickisch GHJ, van Poppel H, de Prijck L et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–970CrossRefPubMed
100.
Minasian LM, Motzer RJ, Gluck L et al. (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow up. J Clin Oncol 11: 1368–1375PubMed
101.
Minervini A, Lilas L, Morelli G et al. (2001) Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int 88: 169–172CrossRefPubMed
102.
Moch H, Gasser T, Amim MB et al. (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer 89: 604–614CrossRefPubMed
103.
104.
Motzer RJ, Michaelson MD, Redman BG et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth facotr receptor and platelet-derived growth facotr receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24CrossRefPubMed
105.
Murphy LJT (1972) The history of urology. CC Thomas Books, Springfield, Ill.
106.
Negrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’immunotherapie. N Engl J Med 338: 1272–1278CrossRefPubMed
107.
Novick AC, Streem S, Montie JE et al. (1989) Conservative surgery for renal cell carcinoma: A single-center experience with 100 patients. J Urol 141: 835–839PubMed
108.
Oberling C, Riviere M, Haguenan F (1959) Ultrastructure of clear cell epitheliomas of the kidney (hypernephroma or Grawitz tumor) and ist implications for the histiogenesis of the tumors. Bull Cancer Assoc Franc 46: 356–358
109.
Oh SW, Yoon YS, Sin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea national health insurance corporation study. JCO 23: 4742–4754CrossRef
110.
Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 25: 500–508CrossRefPubMed
111.
Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166: 1611–1623CrossRefPubMed
112.
Pantuck AJ, Zisman A, Dorey F et al. (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169: 2076–2083CrossRefPubMed
113.
Parwani AV, Husain An, Epstein JI et al. (2001) Low grade myxoid renal epithelial neoplasms with distal nephron differentiation. Hum Pathol 32: 506–512CrossRefPubMed
114.
Pedrazzoli P, Da Prada GA, Giorgiani G et al. (2002) Allogeneic blood stem cell transplantation after a reduced-intensity preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94: 2409–2415CrossRefPubMed
115.
Peters C, Brown GL (1980) The role of lymphadenectomy in the management of renal cell carcinoma. Urol Clin North Am 7: 705–709PubMed
116.
Pischon T, Lahmann PH, Boeing H et al. (2006) Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 118: 728–738CrossRefPubMed
117.
Quesada JR, Swanson DA, Gutterman JU (1985) Phase II study of interferon alpha in metastatic renal cell carcinoma: a progress report. J Clin Oncol 3: 1086–1092PubMed
118.
Ramani AP, Desai MM, Steinberg AP et al. (2005) Complications of laparoscopic partial nephrectomy in 200 cases. J Urol 173: 42–47PubMed
119.
Rayer PFO (1837) Traité des Maladies des Reins. Paris 1837–1841
120.
Rini BI, Zimmerman T, Stadler WM et al. (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20: 2017–2024CrossRefPubMed
121.
Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028–1043CrossRefPubMed
122.
Robin C (1855) Memoire sur l’épitelioma du rein. Gaz Hop 28: 186–194
123.
Robson CJ, Churchill BM, Anderson W (1969) Results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301PubMed
124.
Rohde D (2005) Studienlandschaft Nierenzellkarzinom. Medikamentöse Therapie. Urologe 44: 1423–1429CrossRefPubMed
125.
Schlehofer B, Heuer C, Blettner M et al. (1995) Occupation, smoking and demographic factors and renal cell carcinoma in Germany. Int J Epidemiol 24: 51–57PubMed
126.
Schlehofer B, Pommer W, Mellemgaard A et al. (1996) International renal cell cancer study – VI role of medical and family history. Int J Cancer 66: 723–726CrossRefPubMed
127.
Semb C (1954) Carcinoma of the solitary kidney treated by partial resection: three years observation. Urologia 21: 155
128.
Semelka RC, Shoenhut JP, Margo CM et al. (1993) Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imag 3: 597–602
129.
Shvarts O, Lam JS, Kim HL, Belldegrun AS (2005) Staging of renal cell carcinoma: current concepts. BJU Int 95(Suppl 2): 8–13
130.
Siemer S, Lehmann J, Kamradt J et al. (2004) Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol 171: 2155–2159CrossRefPubMed
131.
Siemer S, Lehmann J, Loch A et al. (2005) Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173: 33–37PubMed
132.
Siminovitch JP, Montie JE, Straffon RA (1982) Lymphadenectomy in renal adenocarcinoma. J Urol 127: 1090–1091PubMed
133.
Stetter R (1887) Demonstration eines extirpierten Pyloruscarcinoms und einer extirpierten carcinomatösen Niere. Verh Dtsch Ges Chir 16: 36
134.
Stoddard CL (1861) Case of encephaloid disease of kidney, removal. Med Surg Reporter 7: 126
135.
Stolle CA, Glenn G, Zbar B et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation 12: 417–423CrossRefPubMed
136.
Störkel S, Eble JN, Adlakha K et al. (1997) Classification of renal cell carcinoma. Cancer 80: 987–989CrossRefPubMed
137.
Studer UE, Scherz S, Scheidegger J et al. (1990) Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 144: 243–245PubMed
138.
Swanson DA, Orovan WL, Johnson DE, Giacco G (1981) Osseous metastasis secondary to renal cell carcinoma. Urology 18: 556–561CrossRefPubMed
139.
Swick M (1929) Darstellung der Niere und Harnwege im Röntgenbild durch intravenöse Einbringung eines neuen Kontraststoffes, des Uroselectans. Klin Wochenschr 8: 2087–2089CrossRef
140.
Targonski PV, Frank W, Stuhldreher D et al. (1994) Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes, and metastases stage 1 and stage 2 patients. J Urol 152: 1389–1392PubMed
141.
Terronea C, Craccoa C, Porpigliaa F et al. (2006) Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49: 324–331CrossRefPubMed
142.
Thompson RH, Cheville JC, Lohse CM et al. (2005) Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104: 53–60CrossRefPubMed
143.
Tsui KH, Shvarts O, Smith RB et al. (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163: 1090–1095CrossRefPubMed
144.
Uchida M, Imaide Y, Sugimoto K et al. (1995) Percutaneous cryosurgery for renal tumors. Br J Urol 75: 132–136PubMed
145.
Ueno NT, Cheng YC, Rondon G et al. (2003) Rapid induction of complete donor chimerism by the use of a reduced intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102: 3829–3836CrossRefPubMed
146.
Umeda T, Miijima T (1986) Phase II study of alpha interferon on renal cell carcinoma: summary of three collaborative trials. Cancer 58: 1231–1235CrossRefPubMed
147.
Van Herpen CM, De Mulder PH (2002) Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol 41: 327–334PubMed
148.
Van Spronsen DJ, de Weijer KJM, Mulders PFA, De Mulder PHM (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti Cancer Drugs 16: 709–717CrossRefPubMed
149.
Vieweg J, Jackson A (2004) Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther 4: 1791–1801CrossRefPubMed
150.
Voelcker F, von Lichtenberg A (1906) Roentgenographie des Nierenbeckens nach Kollargolfüllung. Münch Med Wochenschr 53: 105–107
151.
Volm M, Kastel M, Mattern J, Efferth T (1993) Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in ranl cell carcinomas. Cancer 7: 3981–3987CrossRef
152.
Von Lichtenberg A, Swick M (1929) Klinische Prüfung des Uroselectans. Klein Wochenschr 8: 2089–2091CrossRef
153.
Wade H (1935) Renal tumors. Aust NZ J Surg 5: 3–17
154.
Wagner FB (1946) Arteriography in renal diagnosis: Preliminary report and critical evaluation. J Urol 56: 625
155.
Waldeyer W (1867) Zur Entwicklung von Karzinomen. Arch Pathol Anat Physiol Klein Med 41: 470–523CrossRef
156.
Wille AH, Roigas J, Deger S et al. (2004) Laparoscopic nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. Eur Urol 45: 483–489CrossRefPubMed
157.
Wittekind C, Meyer HJ, Bootz F (2003) TNM Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York
158.
Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434CrossRef
159.
Zincke H, Engen DE, Henning KM, McDonald MW (1985) Treatment of renal cell carcinoma by in situ partial nephrectomy and extracorporeal operation with autotransplantation. May Clin Proc 60: 651
160.
Zisman A, Pantuck A, Chao D et al. (2001) Reevaluation of the 1997 TNM classification for renal carcinoma T1 and T2 cutoff point at 4.5 rather than 7 cm correlates better with clinical outcome. J Urol 166: 54–58CrossRefPubMed
161.
Zisman A, Wieder JA, Pantuck AJ et al. (2003) Renal cell carcinoma with tumor thrombus extension: Biology, role of nephrectomy and response to immunotherapy. J Urol 169: 909–916CrossRefPubMed
162.
Zlotta AR, Wildschutz T, Raviv G et al. (1997) Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 11: 251–258PubMed
Metadaten
Titel
Das Nierenzellkarzinom
verfasst von
PD Dr. A. Haferkamp
D. Rohde
S. C. Müller
H. Rübben
M. Hohenfellner
Publikationsdatum
01.09.2006
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe Sonderheft 4/2006
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-006-1136-1

Weitere Artikel der Sonderheft 4/2006

Der Urologe 4/2006 Zur Ausgabe

Leitthema

Die perkutane Nephrolithotomie

Leitthema

Myelomeningozele – „die nächsten Jahre …“

Editorial/Leitthema

Zum 100 jährigen Jubiläum der Deutschen Gesellschaft für Urologie

Leitthema

Extrakorporale Stoßwellenlithotripsie

Editorial

Reflections on a successful relationship

Leitthema

100 Jahre Prostakarzinom: gestern – heute – morgen

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise